Marshall Wace, LLP Aptinyx Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	BUY	$2.39 - $3.5 $47,264 - $69,216	19,776 New	19,776 $56,000
Q2 2020 Aug 13, 2020	SELL	$1.99 - $4.4 $24,662 - $54,529	-12,393 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.81 - $5.03 $238,252 - $662,103	-131,631 Reduced 91.4%	12,393 $27,000
Q4 2019 Feb 14, 2020	SELL	$2.84 - $4.25 $202,193 - $302,578	-71,195 Reduced 33.08%	144,024 $493,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.08 $273,303 - $371,692	-91,101 Reduced 29.74%	215,219 $751,000
Q2 2019 Aug 14, 2019	BUY	$2.95 - $4.38 $162,152 - $240,755	54,967 Added 21.87%	306,320 $1.02 Million
Q1 2019 May 14, 2019	BUY	$3.99 - $19.33 $1 Million - $4.86 Million	251,353 New	251,353 $1.02 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.